<html>
  <div class="bg-white p-4 rounded-md shadow-md">
    <h2 class="text-lg font-bold mb-2">Safety Information</h2>
    <p class="text-gray-600">Oncozen has a robust safety profile, with a low incidence of severe adverse events.</p>
    <ul class="list-disc pl-4 mb-4">
      <li class="text-gray-600">In clinical trials, the most common adverse events were mild to moderate and reversible.</li>
      <li class="text-gray-600">Oncozen demonstrated a low risk of severe neutropenia, anemia, and thrombocytopenia compared to other oncology treatments.</li>
      <li class="text-gray-600">No cumulative toxicity was observed, and dose reductions or interruptions were rarely necessary.</li>
    </ul>
    <p class="text-gray-600">The safety profile of Oncozen supports its use in a variety of clinical settings, including patients with comorbidities and those who have experienced treatment-related toxicities.</p>
  </div>
</html>